Summary
What do they do? Glenn Burke Wellness Clinic is a project of the Center, not a separate legal recipient. Official services include HIV/STI testing and treatment, PrEP/PEP enrollment, rapid ART linkage, vaccinations and navigation, in collaboration with LifeLong Medical Care and Bay Area Community Health. Services can be free or payer-covered, with county, foundation and Gilead support. More
Why this approach interests us
- The Glenn Burke clinic offers PrEP, treatment and rapid ART linkage with experienced clinical partners. Additional sustained access can prevent infection and shorten illness.
Our main reservations
- Starts, retention, positivity, patient alternatives and donor-created capacity are unobserved. The favorable10% world supplies99.21% of signed expected benefit.
What do you get for your dollar?
The research list uses the central scenario: $487,415,791 per 10 Bay QALYs. Signed mixture $34,551,066 per 10 Bay QALYs; central $487,415,791. Whole $4,957,230 expense is retained against partial quantified clinical health, not complete expected value. Inspect the model and assumptions.
- whole expense
- $4,957,230 — Calendar2024; all programs and administration retained.
- bay mixture
- $34,551,066 — Per10 Bay QALYs; partial clinical health.
- central
- $487,415,791 — Distinct from weighted signed mixture.
- favorable tail
- 99.21% — Contribution of the10% favorable world.
1. What do they do?
Glenn Burke Wellness Clinic is a project of the Center, not a separate legal recipient. Official services include HIV/STI testing and treatment, PrEP/PEP enrollment, rapid ART linkage, vaccinations and navigation, in collaboration with LifeLong Medical Care and Bay Area Community Health. Services can be free or payer-covered, with county, foundation and Gilead support.
Separate tests from clinical people
Use1,046 HIV-tested patients only as a scale anchor. Do not add686 syphilis and5,606 chlamydia/gonorrhea testing counts as unique clients or cured infections.
Model retained, additional care
Explicit uncertain starts, protected person-years, positivity and effective treatment bridge testing to outcomes; ART-positive and PrEP-negative pools are separated.
Limit health and attribution
Finite treated-era HIV morbidity and short STI symptom relief only. Retain partner contribution, public baseline, whole cost and signed harm.
Scope of this review. Housing, community support, youth/senior programs, therapy, vaccines, doxyPEP, gender care and other health pathways remain unquantified, not zero. This is not a complete organization return.
2. Monitoring and information sharing
Whole legal recipient EIN82-2258008
Original calendar2024 Form990. Expense $4,957,230; reported HIV testing1,046, syphilis686, chlamydia/gonorrhea5,606.
Our assessment. Tests can repeat by person, anatomical site and time. No observed PrEP starts, new HIV diagnoses, cure or retention inferred.
Glenn Burke clinic clients and joint providers
Current official clinic service page. PrEP/PEP, HIV/STI treatment, rapid ART linkage and payer enrollment are offered with LifeLong/BACH and public/private funders.
Our assessment. Actual care mechanism, but no annual completed-care or cash-created capacity denominator. Do not duplicate partner impact.
High-risk MSM in England; deferred comparator incidence9/100 person-years
PROUD open-label randomized immediate versus deferred PrEP. 1.2 versus9.0 HIV infections/100 person-years;86% relative reduction,90%CI64–96.
Our assessment. Local testing patients are not this selected high-risk cohort. Model uses lower .5–4% risk priors and separate conditional protection/retained time; it does not use the ITT estimate plus an extra adherence penalty.
People taking oral/injectable PrEP as prescribed
CDC clinical guidance synthesizing PrEP evidence. Sexual acquisition reduction about99% with prescribed use.
Our assessment. Not99% benefit per referral. Retention, eligibility and alternative access are unknown; local protection .7–.99 is judgment.
HIV-positive adults with CD4 above500
START randomized immediate versus deferred ART. Composite serious AIDS/non-AIDS/death endpoint1.8% versus4.1%, HR.43.
Our assessment. Not a2.3% mortality reduction or QALY coefficient. Modern prompt alternative care is a stronger comparator than prolonged trial deferral; only finite morbidity proxy modeled.
People with chlamydia, often asymptomatic
CDC treatment guidelines. Prompt effective treatment is recommended; multiple-site/repeat tests and asymptomatic infections are common.
Our assessment. No test-to-health shortcut. Model restricts benefit to additional effective treatment of symptomatic nonoverlapping episodes; permanent complications and transmission unquantified.
3. Qualitative assessment
The Glenn Burke clinic offers PrEP, treatment and rapid ART linkage with experienced clinical partners. Additional sustained access can prevent infection and shorten illness.
Key reservations
- Full expense with partial health is not complete expected value.
- Almost all signed expected benefit comes from a jointly optimistic10% world.
- HIV-tested patients do not establish new PrEP starts, unique STI episodes or ART retention.
- Large partner/public-funded baseline and unknown marginal private response.
- Finite morbidity-only HIV valuation is highly uncertain and omits survival rather than assuming it zero.
Benefits not included in our estimate
- Housing, community support and dignity—unquantified, not zero.
- Mental-health courses inferred from therapy/social-group reach.
- Vaccination, doxyPEP and gender-care health without completed-care denominators.
- Secondary HIV/STI transmission and lifetime untreated-AIDS survival.
- PrEP benefits for patients already HIV-positive or repeat test counts as new people.
4. What do you get for your dollar?
$34,551,066 per10 Bay QALYs
Signed annual BayQ 1.434754559425406; all-beneficiaryQ 1.4349579211273749. Central modeled clinical people 836.8000000000001, PrEP starts 165.68640000000002, protected person-years 82.84320000000001. None is an observed completed-care count.
A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.
How we calculate the estimate
Finite signed clinical component: gift / whole expense × cash response × partner contribution × Bay share × [PrEP infections avoided × finite HIV morbidity Q + earlier ART morbidity Q + nonoverlapping STI symptom Q − per-person harm]
0.0028942666759972932 Bay QALYs per $10,000
Model inputs and assumptions
- Whole expense
- $4,957,230 (range: Calendar2024). Original filed expense. No clinic-only substitution; partner resources outside recipient are not fully valued. Filed.
- HIV-tested patients
- 1,046 (range: 2024 reported service count). Not PrEP starts or a verified all-service unique denominator. Other tests are not added. Reported.
- unique
- 0.8 (range: 0.6–1). Fraction of HIV-tested patient count representing unique index clinical people; repeat testing may already be deduplicated, so .8 is uncertainty rather than an observed correction. Analyst judgment; not observed local effect.
- prepShare
- 0.2 (range: 0.05–0.4). Fraction of modeled HIV-negative people starting a PrEP program; not the observed testing-to-start conversion. Analyst judgment; not observed local effect.
- prepYears
- 0.5 (range: 0.25–0.8). Mean retained protected person-years per starter within one year; no separate adherence factor. Analyst judgment; not observed local effect.
- risk
- 0.015 (range: 0.005–0.04). Annual untreated/comparator HIV acquisition risk in retained sexual-risk cohort. .5–4% is below PROUD's high-risk9% deferred incidence; local risk is not measured. Analyst judgment; not observed local effect.
- protection
- 0.9 (range: 0.7–0.99). Conditional efficacy during retained protected time. CDC99% requires prescribed use; .7–.99 judgments allow imperfect local protection. Not PROUD's ITT86% multiplied by a second adherence rate. Analyst judgment; not observed local effect.
- prepAccess
- 0.4 (range: 0.2–0.7). Fraction of protection not supplied by another clinic or current coverage. Analyst judgment; not observed local effect.
- hivUtility
- 0.1 (range: 0–0.15). Average treated-era morbidity utility difference after an averted infection, not an untreated-AIDS disability weight. Analyst judgment; not observed local effect.
- hivYears
- 10 (range: 5–20). Finite effective morbidity years per infection avoided; includes persistence/survival/discount uncertainty in a single effective-year prior. No lifetime survival award or secondary transmission. Analyst judgment; not observed local effect.
- positive
- 0.01 (range: 0.005–0.02). Fraction of unique clinical people already HIV-positive, removed from PrEP pool; not observed new diagnoses. Analyst judgment; not observed local effect.
- artLink
- 0.7 (range: 0.5–0.9). Fraction of HIV-positive pool entering supported ART care, not documented starts. Analyst judgment; not observed local effect.
- artAccess
- 0.5 (range: 0.2–0.7). Share of ART access earlier/additional to ordinary clinical alternatives; includes already-in-care patients receiving no additional benefit. Analyst judgment; not observed local effect.
- artUtility
- 0.05 (range: 0–0.1). Finite morbidity utility improvement from earlier care; analyst proxy, not START composite-event rate treated as QALYs. Analyst judgment; not observed local effect.
- artYears
- 0.5 (range: 0.25–2). Finite duration of earlier morbidity improvement before alternative care. Analyst judgment; not observed local effect.
- stiEpisodes
- 0.2 (range: 0.1–0.4). Nonoverlapping treatable STI episodes per clinical person; does not multiply all test counts. Analyst judgment; not observed local effect.
- stiTreat
- 0.8 (range: 0.5–0.95). Fraction of modeled episodes receiving effective treatment. Analyst judgment; not observed local effect.
- stiSymptom
- 0.3 (range: 0.2–0.5). Fraction producing removable short-term symptoms; asymptomatic infections are common. Analyst judgment; not observed local effect.
- stiAccess
- 0.5 (range: 0.2–0.7). Fraction of treatment benefit not obtained promptly elsewhere. Analyst judgment; not observed local effect.
- stiUtility
- 0.1 (range: 0–0.2). Symptomatic utility loss relieved; unmeasured local proxy. Analyst judgment; not observed local effect.
- stiYears
- 0.02 (range: 0.01–0.05). Short incremental symptom duration relieved, not duration of permanent complications. Analyst judgment; not observed local effect.
- partner
- 0.5 (range: 0.3–0.7). Recipient contribution share of jointly produced clinical benefit. Avoids assigning LifeLong/BACH/provider impact wholly to this legal recipient; not an external-resource cost valuation. Analyst judgment; not observed local effect.
- funding
- 0.4 (range: 0–0.65). Ordinary cash response relative to existing whole budget, separate from patient alternative care and partner attribution. Analyst judgment; not observed local effect.
- bay
- 0.98 (range: 0.95–1). Bay share of benefits and harms, .95–1; Oakland footprint is not verified residences. Analyst judgment; not observed local effect.
- harm
- 0.00005 (range: 0–0.0005). Independent QALY burden per modeled person from delivery/adverse experiences, including people without modeled clinical gains; not a local observed harm rate. Analyst judgment; not observed local effect.
- Signed subjective weights
- .2 funding-null; .15 clinical-null; .1 harm (range: .25 cautious; .2 central; .1 favorable). Locked before first output, not calibrated probabilities; joint scenarios allow correlation. Judgment.
$10,000 analytic illustration—not a purchased clinical package
- funding_null: No positive finite price per10; weight 0.2. Annual BayQ 0; PrEP component 0.4473532800000002, ART 0.07322, STI 0.040166400000000005, harm 0.04184, before partner/cash/Bay.
- clinical_null: No positive finite price per10; weight 0.15. Annual BayQ 0; PrEP component 0, ART 0, STI 0, harm 0, before partner/cash/Bay.
- harm: No positive finite price per10; weight 0.1. Annual BayQ -0.08200640000000002; PrEP component 0, ART 0, STI 0, harm 0.41840000000000005, before partner/cash/Bay.
- cautious: No positive finite price per10; weight 0.25. Annual BayQ -0.0033742511943750005; PrEP component 0.0013660106250000003, ART 0.0015690000000000005, STI 0.0006276000000000003, harm 0.06276000000000001, before partner/cash/Bay.
- central: $487,415,791 per10; weight 0.2. Annual BayQ 0.10170433728000004; PrEP component 0.4473532800000002, ART 0.07322, STI 0.040166400000000005, harm 0.04184, before partner/cash/Bay.
- favorable: $3,482,527 per10; weight 0.1. Annual BayQ 14.234578947679998; PrEP component 27.278608895999994, ART 2.6359200000000005, STI 1.39118, harm 0.02092, before partner/cash/Bay.
- without_favorable: $3,949,402,001. Other worlds renormalized, no retuning.
- half_finite_hiv_horizon: $61,550,803. Diagnostic only; exact inputs and full outputs saved separately.
- double_resources: $69,102,133. Diagnostic only; exact inputs and full outputs saved separately.
- central_hiv_clinical_all_worlds: $142,065,779. Diagnostic only; exact inputs and full outputs saved separately.
- prep_only: $39,751,799. Diagnostic only; exact inputs and full outputs saved separately.
Uncertainty. Favorable share 99.2126%. Declared subjective mass below $1M and $100k is zero, not calibrated impossibility. All-beneficiary price $34,546,170 differs from Bay. Finite HIV morbidity uses effective years, not additional survival; no infection automatically earns a lifetime. PrEP risk and efficacy apply once during retained protected time. ART-positive clients cannot also be PrEP-negative clients. STI relief is restricted to residual symptoms, not HIV complications, with no permanent disability or secondary transmission. A prevention benefit and treatment benefit for distinct conditions may occur in one person but must not count the same utility loss twice.
5. Funding and previous grants
HOLD giving recommendation. No priced additional clinical offer is verified, and even the favorable modeled world exceeds $1M per 10 Bay QALYs.
2024 revenue $4,325,439; government contributions $548,486; program fees $1,321,469; net assets $411,634 versus liabilities $4,171,979. The $631,791 deficit is not a marginal funding offer. Official clinic names county/Gilead/foundation support and LifeLong/BACH collaboration. Partner contribution shares health credit; funding estimates additional activity; patient access estimates substitution by alternative care. They are distinct but correlated judgments. No verified restricted gift pathway or treatment price. Whole accounting expense is not full economic resource cost; doubling resources is illustrative only.
This review does not establish a verified marginal funding offer or a complete history of grants.
We have not verified a suitable donation route for this reviewed activity. Confirm the legal recipient and intended allocation before donating.
6. Sources
- Original Oakland LGBTQ Community Center FY2024 Form990. IRS via ProPublica. Primary. Published: Filed November17,2025; retrieved: 2026-09-11.
- Glenn Burke Wellness Clinic services, funding and partners. Oakland LGBTQ Community Center. Primary. Published: Undated current page; retrieved: 2026-09-11.
- Clinical guidance for PrEP. CDC. Primary. Published: Current guidance, retrieved date below; retrieved: 2026-09-11.
- PROUD randomized PrEP trial. McCormack et al. / UCL. Primary. Published: 2016; retrieved: 2026-09-11.
- Initiation of antiretroviral therapy in early asymptomatic HIV infection. INSIGHT START Study Group / NEJM. Primary. Published: 2015; retrieved: 2026-09-11.
- Chlamydial infections treatment guidelines. CDC. Primary. Published: 2021 guidelines, current page; retrieved: 2026-09-11.
Annual expenses: years and sources
Average annual expenses (three consecutive fiscal years): $4,099,681. Organization size is separate from the modeled cost-effectiveness of a donation.
Oakland Lgbtq Community Center Inc
Form 990/990-EZ reported whole-entity expenses; includes program, administration and fundraising costs, but excludes any costs netted against revenue.
Latest original return and prior-year comparative combined with earlier filing data.